Wed Jan 29 16:50:00 UTC 2025: ## Senators Must Question Kennedy on Patent Seizure Plan, Critics Warn
**Washington, D.C.** – As Robert F. Kennedy Jr.’s confirmation hearings for the Department of Health and Human Services (HHS) begin, concerns are rising over his stance on forcibly relicensing patents. Critics argue that his reported openness to seizing drug company patents and relicensing them to generic manufacturers could severely damage the American high-tech economy.
While Kennedy’s team denies reports of his support for this policy, commentators like [Author’s Name, from the original text] urge senators to directly question him on the issue during his confirmation hearings before the Senate Finance and HELP Committees. This policy, they claim, would effectively implement price controls on numerous medications by misinterpreting the Bayh-Dole Act.
The Bayh-Dole Act, enacted in 1980, allows federally funded universities and non-profits to retain patents on their research and license them to private companies. This has spurred the development of over 200 new drugs and vaccines and the creation of thousands of startups, making the U.S. a global leader in medical innovation. The act includes a “march-in” provision allowing the government to seize and relicense patents under limited, emergency circumstances, but this has never been used.
Opponents argue that Kennedy’s proposed expansion of this provision would create widespread uncertainty and discourage investment in research and development. They contend that the arbitrary seizure of patents would not only impact the pharmaceutical industry but also harm other high-tech sectors reliant on patent licensing agreements. This, they warn, would ultimately stifle innovation and prevent taxpayer-funded research from translating into beneficial products for consumers. The senators’ questioning, therefore, is crucial to determine Kennedy’s understanding of the potential ramifications of such a policy.
First Piper 